Aragen’s experienced team investigates different animal protocols, optimizing planning and experimental design to ensure clients get the most out of their in vivo studies. Our excellent infrastructure and agile operational model enables the quick allocation of appropriate space with technical staff to accelerate research programs. We provide specialized platforms and technical expertise, including ex vivo/in vitro testing and histological preparations. In addition to disease models in a multitude of therapeutic areas, we also undertake non-GLP pharmacokinetic (PK), pharmacodynamic (PD), and toxicology screens.
We work out of a state-of-the-art 15,000 sq ft facility dedicated to in vivo pharmacology, ex vivo and in vitro cell based analysis. These resources, combined with our specialization in animal handling and small animal procedures, ensure successful outcomes of preclinical studies.
Aragen is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). Our in vivo pharmacology consists of non-GLP studies performed exclusively in rodent models. We have a long tradition in the humane and proper use of laboratory research animals for biological and biomedical research. The Institutional Animal Care and Use Committee (IACUC) serves as an independent oversight committee responsible for monitoring all associated animal care and use at Aragen. Accrediting agencies like the USDA and the Public Health Service/National Institutes of Health/Office of Lab Animal Welfare (OLAW) monitor the IACUC’s operations. Aragen also holds a Controlled Substance License from the US Department of Justice/Drug Enforcement Administration (DEA).
Aragen has a portfolio of in vivo fibrosis models and world class expertise to support clients in the development of anti-fibrotic therapeutic or prophylactic candidates. In hundreds of studies over the course of more than a decade, we have evaluated the efficacy of test compounds spanning several modalities (small molecules, biologics, RNA therapeutics, exosomes etc.) on a variety of assay platforms, ultimately resulting in INDs for our clients.
Aragen experts design and manage infectious disease programs that maximize a drug candidate’s probability of success. Our team’s extensive experience results in a thorough understanding of infectious disease modeling, allowing clients to creatively test compound activity, design new delivery mechanisms, and explore novel vaccine strategies for a variety of infectious diseases.
Infectious Disease Models
Pseudovirus System for SARS-CoV-2
The vesicular stomatitis virus (VSV)-based pseudovirus system incorporating the Spike protein from SARS-CoV-2 is a useful tool for the analysis of serum from vaccine studies, monoclonal antibodies or therapeutics that impact the entry of SARS-CoV-2 into cells. In this system the VSV genome has been modified to eliminate the expression of its attachment/fusion protein (G protein). The attachment/fusion proteins from heterologous viruses can then be expressed from a plasmid during an infection with the modified VSV. The emerging virus particles contain a functional SARS-CoV-2 Spike protein on the surface of the VSV. This system can be quickly updated with emerging original SARS-COV-2 as well as the variants on the Spike protein. Experts in virology perform these assays in BSL2 laboratories.
Aragen offers a diverse range of oncology disease models and services to customize study designs for specific projects. These include human xenograft tumor models as well as the more complex sub-renal capsule, patient-derived xenograft (PDX), and syngeneic tumor models.
|Tissue Type||Human Cell Line|
|Burkitt’s lymphoma||Raji, Raji-Luc-GFP|
|Acute myeloid leukemia||Kasumi-1|
|B cell leukemia||NALM6, SUDHL-10|
|Multiple myeloma||KG-1, NCI-H929, U266, MM.1s, RPMI-8226|
|Colon adenocarcinoma||HT-29, HCT-116, HCT-116 Luc-GFP, Colo 205, SW480|
|Lung (NSCLC)||A549, NCI-H226, NCI-H1299, NCI-H358, NCI-H1944, A549-Luc-GFP|
|Lung anaplastic carcinoma||Calu-6|
|Lung adenocarcinoma||NCI-H1573, NCI-H292|
|Renal cell carcinoma||Caki-1, 786-O|
|Hepatocellular carcinoma||Hep G2, Hep 3B|
|Pancreatic cancer||BxPC-3, BxPC-3-Luc-GFP, Mia Paca-2-Luc|
|Ovarian cancer||SKOV-3, SKOV-3-Luc, OVCAR-3|
|Prostate cancer||LNCaP, LNCaP-Luc, 22rv.1|
|Breast cancer||MDA-MB-468, MDA-MB-231, MDA-MB-231-Luc, MCF-7, MCF-7 Luc, BT-474|
|Tumor Origin||Murine Cell Line|
|Breast||4T1, 4T1-Luc, EMT-6|
Our preclinical research in immunology and inflammation focuses on arthritis and autoimmunity. Aragen scientists have expertise in preclinical investigations of the joints and lung functions in vivo, including bronchoalveolar lavage, cytology, immunohistochemistry, and analysis of biochemical, immunological and molecular parameters. Strong collaborations with various academic, governmental and industrial laboratories have enabled the development of several experimental models of immunology and inflammatory diseases.
Combining years of experience in the development of respiratory disease therapeutics with the latest tools and assays, we help accelerate biotherapeutic or small molecule drug development. Aragen’s validated rodent models enable the evaluation of the potential efficacy of novel asthma, anti-inflammatory, anti-fibrotic and bronchodilator agents targeting lung fibrosis.
Our rodent asthma models include induction by ova or other allergens (cedar pollen, dust mote antigen). Models can range from mild to severe disease, to evaluate a range of treatment options.
Rodent models that test efficacy and safety in preclinical studies provide a critical component to the development of anti-RSV antibodies, small molecules and vaccines.
A well characterized ALI model induced by combined administration of LPS and Zymosan, with detailed end results of bronchoalveolar lavage infiltrate, cytokine analysis, hypoxia measurements and histology with capability of lung function analysis.
Bleomycin induction causes quick inflammatory and fibrotic reactions in rodent lungs, successfully replicating many of the pathological characteristics associated with IPF, including abnormal deposition and accumulation of collagen in lung tissue.
A rodent model induced by the administration of crystalline silico dioxide (or silica) displays many pathophysiological features of chronic inflammation and pulmonary fibrosis.